Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 4/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.38 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | CES2 | O00748 | 1/20 | 0.34 |
| ▸ | CES1 | P23141 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | TLR2 | O60603 | 1/20 | 0.34 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30106737 | 1.00 | ERN1 (0.57) | ERN1MEN1LMNATHRBBLM | |
| SCHEMBL29139204 | 0.83 | KMT2A (0.58) | ERN1MEN1LMNATHRBBLM | |
| SCHEMBL13887136 | 0.77 | NFE2L2 (0.41) | ERN1NFE2L2ALDH1A1GRIN2DGRIN3B | |
| SCHEMBL17023603 | 0.77 | ALDH1A1 (0.44) | ERN1MEN1LMNATHRBBLM | |
| SCHEMBL154794 | 0.76 | ERN1 (0.61) | ERN1MEN1LMNATHRBBLM | |
| SCHEMBL1655785 | 0.76 | TDP1 (0.50) | ERN1MEN1LMNATHRBBLM | |
| SCHEMBL30039913 | 0.75 | — | — | |
| SCHEMBL29540911 | 0.75 | — | — | |
| SCHEMBL20465749 | 0.75 | — | — | |
| SCHEMBL87096 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118894867-A | Preparation of 12-fluorocamptothecin derivative and application thereof in anti-tumor aspect | 兰州大学 | 2024-11-05 | — | — | CN | claimed |
| CN-107522766-A | One kind has ursolic acid quinolyl hydrazide derivatives of antitumor activity and its preparation method and application | 南京林业大学 | 2017-12-29 | — | — | CN | claimed |
| EP-4622967-A1 | COMPOUNDS THAT INHIBIT PKMYT1 | Exelixis, Inc. (US) | 2025-10-01 | — | — | EP | disclosed |
| US-20250171431-A1 | HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE | HORIZON THERAPEUTICS IRELAND DAC (IE) | 2025-05-29 | — | — | US | disclosed |
| CN-119585247-A | Bicyclic heterocyclic amide inhibitors of nav1.8 for the treatment of pain | 赛特温治疗公司 | 2025-03-07 | — | — | CN | disclosed |
| EP-4514789-A1 | <SUP2/>? <SUB2/>?V?BICYCLIC HETEROCYCLIC AMIDE INHIBITORS OF NA1.8 FOR THE TREATMENT OF PAIN | SiteOne Therapeutics, Inc. (US) | 2025-03-05 | — | — | EP | disclosed |
| US-12220421-B2 | Inhibitors of C. difficile spore germination | THE BOARDS OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, LAS (US) | 2025-02-11 | — | — | US | disclosed |
| WO-2025030163-A1 | HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE | HORIZON THERAPEUTICS IRELAND DAC (IE) | 2025-02-06 | — | — | WO | disclosed |
| CN-118894867-A | Preparation of 12-fluorocamptothecin derivative and application thereof in anti-tumor aspect | 兰州大学 | 2024-11-05 | — | — | CN | disclosed |
| EP-4398890-A2 | INHIBITORS OF C. DIFFICILE SPORE GERMINATION | Abel-Santos, Ernesto (US) | 2024-07-17 | — | — | EP | disclosed |
| WO-2024112853-A1 | COMPOUNDS THAT INHIBIT PKMYT1 | EXELIXIS, INC. (US) | 2024-05-30 | — | — | WO | disclosed |
| US-20100331306-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100331306-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2010-12-30 | — | — | US | disclosed |
| WO-2010151740-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2010-12-29 | — | — | WO | disclosed |
| WO-2010151740-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2010-12-29 | — | — | WO | disclosed |
| US-5532374-A | Method of preparation of bis-quinolines | HITACHI CHEMICAL COMPANY, LTD. (JP) | 1996-07-02 | — | — | US | disclosed |
| EP-0093611-B2 | Composite plasmid | AJINOMOTO KK (JP) | 1995-03-22 | — | — | EP | disclosed |
| EP-0093611-B1 | COMPOSITE PLASMID | AJINOMOTO CO., INC. (JP) | 1987-07-22 | — | — | EP | disclosed |
| US-4514502-A | DRUG RESISTANCE | AJINOMOTO CO., INC. (JP) | 1985-04-30 | — | — | US | disclosed |
| EP-0093611-A1 | Composite plasmid | AJINOMOTO CO., INC. (JP) | 1983-11-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12220421-B2 | Inhibitors of C. difficile spore germination | CDC37, SI, DAD1 | ERN1 2577/4885MEN1 4513/4885LMNA 4332/4885 |
| US-20100331306-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, BCL9, MALT1 | ERN1 3475/4885MEN1 1596/4885LMNA 2321/4885 |
| US-20250171431-A1 | HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE | IGF1R, TRHR, TSHR | ERN1 2399/4885MEN1 160/4885LMNA 3056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.